Given that this gene is upregulated in most cancers, including LUSC, we suggest that ALYREF could contribute to the formation of immunodeficiency niches by reducing the number of tumor-infiltrating cells, thus exacerbating LUSC progression. Here, ALYREF is linked to immune system disorder.